$RUBY on NASDAQ
November 02, 2022
Rubius Therapeutics Announces Process to Explore Strategic Alternatives and Leadership Changes
September 19, 2022
Rubius Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference
September 13, 2022
Rubius Therapeutics Announces Strategic Update
September 12, 2022
Rubius Therapeutics to Provide Strategic Update
August 09, 2022
Rubius Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
July 26, 2022
Rubius Therapeutics to Announce Second Quarter 2022 Financial Results
July 19, 2022
HotSpot Therapeutics Appoints Jose Carmona to Board of Directors
July 14, 2022
Rubius Therapeutics Appoints Susanne Schaffert, Ph.D., to its Board of Directors
June 22, 2022
Rubius Therapeutics Presents Updated Data from its Type 1 Diabetes Preclinical Program at the Federation of Clinical Immunology Societies (FOCIS) 2022 Annual Meeting
June 01, 2022
Rubius Therapeutics to Present at the Jefferies Global Healthcare Conference
May 26, 2022
Rubius Therapeutics to Present Trials in Progress Poster for the Phase 1/2 Clinical Trial of RTX-224 in Select Advanced Solid Tumors at the 2022 American Society of Clinical Oncology Annual Meeting
May 24, 2022
Rubius Therapeutics Appoints Noubar Afeyan as Chairman of its Board of Directors
May 10, 2022
Rubius Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
April 26, 2022
Rubius Therapeutics to Announce First Quarter 2022 Financial Results
April 08, 2022
Rubius Therapeutics Reports Updated Clinical Data at AACR from the Ongoing Monotherapy Phase 1 Arm of the Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors Demonstrating Single-Agent Activity and Favorable Tolerability
April 07, 2022
Rubius Therapeutics to Host Investor Webcast to Discuss Updated Clinical Data at AACR from the Ongoing Monotherapy Phase 1 Arm of the Phase 1/2 Clinical Trial of RTX-240 in Patients with Advanced Solid Tumors on April 8, 2022, at 1:15 PM ET
March 08, 2022
Rubius Therapeutics to Present Updated Results from Single-Agent Phase 1 Clinical Trial of RTX-240 at the American Association of Cancer Research Annual Meeting
February 25, 2022
Rubius Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
February 14, 2022
Rubius Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results
February 01, 2022
Rubius Therapeutics to Present at the Virtual Guggenheim Healthcare Talks and SVB Leerink Global Healthcare Conference in February 2022
January 13, 2022
Rubius Therapeutics Announces Dosing of First Patient in Phase 1/2 Trial of RTX-224, a Broad Immune Agonist, for the Treatment of Certain Solid Tumors
January 10, 2022
Rubius Therapeutics Recaps 2021 Achievements and Outlines 2022 Objectives Across the RED PLATFORM at the 40th Annual J.P. Morgan Healthcare Conference
January 04, 2022
Rubius Therapeutics to Present at the Virtual 40th Annual J.P. Morgan Healthcare Conference
December 16, 2021
Rubius Therapeutics to Highlight the Power of its RED PLATFORM®, Significant Advances Across Red Cell Therapeutic Oncology Pipeline and New Type 1 Diabetes Program at Platform and Pipeline Day
December 02, 2021
Rubius Therapeutics Named to the List of Top Places to Work in Massachusetts by the Boston Globe and Top 3 Best Places to Work in Rhode Island by Providence Business News
December 01, 2021
Rubius Therapeutics to Host Virtual Preclinical Pipeline and Platform Technology Day on December 16, 2021
November 23, 2021
Rubius Therapeutics to Participate in Evercore ISI 4th Annual HealthCONx Conference
November 12, 2021
Rubius Therapeutics Presents Preclinical Data for RTX-224, a Broad Immune Costimulatory Agonist, at the Society for Immunotherapy of Cancer’s Annual Meeting
November 09, 2021
Rubius Therapeutics to Participate in Jefferies London Healthcare Conference
November 08, 2021
Rubius Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
October 28, 2021
Rubius Therapeutics to Announce Third Quarter 2021 Financial Results
October 01, 2021
Rubius Therapeutics Announces Preclinical Data for RTX-224, a Broad Immune Costimulatory Agonist, to be Presented at the Society for Immunotherapy of Cancer’s Annual Meeting
September 01, 2021
Rubius Therapeutics to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference and H.C. Wainwright 23rd Annual Global Investment Conference in September 2021
August 30, 2021
Rubius Therapeutics Appoints Jim Jogerst as Chief Business Officer
August 09, 2021
Rubius Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
July 29, 2021
Rubius Therapeutics Appoints Dannielle Appelhans as Chief Operating Officer
July 22, 2021
Rubius Therapeutics to Announce Second Quarter 2021 Financial Results
July 15, 2021
Rubius Therapeutics Announces Publication of RTX-240 Preclinical Data in Cancer Immunology, Immunotherapy
June 23, 2021
Rubius Therapeutics Announces First Patient Dosed with RTX-240 in Combination with KEYTRUDA® (pembrolizumab) in Ongoing Phase 1/2 Clinical Trial for the Treatment of Advanced Solid Tumors
May 20, 2021
Rubius Therapeutics to Participate in Jefferies Virtual Healthcare Conference
May 19, 2021
Rubius Therapeutics to Present Trials in Progress Poster on the Phase 1 Clinical Trial of RTX-321 for HPV 16-Positive Cancers at the 2021 American Society of Clinical Oncology Annual Meeting
May 12, 2021
Rubius Therapeutics Announces Publication of RTX-321 Preclinical Data in Nature Communications
May 10, 2021
Rubius Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
April 26, 2021
Rubius Therapeutics to Announce First Quarter 2021 Financial Results
April 12, 2021
Rubius Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of RTX-321 for the Treatment of HPV 16-Positive Cancers
April 09, 2021
Rubius Therapeutics Presents Initial Clinical Results from the Ongoing Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors at the American Association of Cancer Research Virtual Annual Meeting
March 16, 2021
Rubius Therapeutics Prices Upsized Public Offering of Common Stock
March 15, 2021
Rubius Therapeutics Announces Proposed Public Offering of Common Stock
March 15, 2021
Rubius Therapeutics Reports Initial Clinical Data from Ongoing Phase 1/2 Trial of RTX-240 in Patients with Advanced Solid Tumors, Demonstrating Single-Agent Activity
March 12, 2021
Rubius Therapeutics Announces Webcast to Review Initial Clinical Data from Ongoing Phase 1/2 Trial of RTX-240 in Patients with Advanced Solid Tumors
- No Recent Filings Found.
